Literature DB >> 2249372

Extrahepatic metabolism of morphine occurs in humans.

J X Mazoit1, P Sandouk, J M Scherrmann, A Roche.   

Abstract

The pharmacokinetics of morphine was studied in six patients in whom a radiologic localization of an insulinoma was to be performed under general anesthesia. Sampling was done in the peripheral artery, the mesenteric vein in five of the six patients, the hepatic vein, and the peripheral vein, as well as in urine. Hepatic blood flow was estimated by an indocyanine green infusion technique at the end of the radiologic procedure. Morphine terminal half-life was 92 +/- 9 minutes, total body clearance was 1260 ml.min-1, and the hepatic extraction ratio was 0.65 +/- 0.11. No concentration gradient was observed between the artery and the superior mesenteric vein, showing that no gut wall metabolism of morphine occurred. The total body clearance exceeded the hepatic clearance by 38%. It was concluded that the extrahepatic extraintestinal clearance of morphine probably occurred through the kidney.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2249372     DOI: 10.1038/clpt.1990.203

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

1.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

2.  Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.

Authors:  J I Macdonald; S M Wallace; V Mahachai; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 4.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 6.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 7.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 8.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

9.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications.

Authors:  L L von Moltke; D J Greenblatt; R I Shader
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.